STOCKWATCH
·
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Corporate GovernanceApr 28, 2026, 06:07 AM

Corvex (MOVE) Amends 10-K; Details Executive/Director Comp Changes Amid Liquidity Issues

AI Summary

Corvex, Inc. (MOVE) filed an Amendment No. 1 to its 2025 Annual Report on Form 10-K, primarily updating information on directors, executive officers, corporate governance, and compensation. The company disclosed that due to liquidity challenges in 2025, it offered restricted stock units (RSUs) and later discounted stock options with an exercise price of $1.25 per share to executive officers and non-employee directors in lieu of cash salary and fees. The amendment also details recent management changes, including the appointment of Jay Crystal as CEO, John Mastrototaro's transition to COO, and the termination of former CTO Michael Leabman. Additionally, new compensation policies for both executives and directors for 2026 were adopted.

Key Highlights

  • Corvex (MOVE) filed an Amendment No. 1 to its 2025 Annual Report on Form 10-K, updating Part III items.
  • Due to 2025 liquidity challenges, RSUs and discounted options were granted to executives and directors in lieu of cash.
  • Discounted options have an exercise price of $1.25 per share and are exercisable until June 30, 2026.
  • Jay Crystal was appointed CEO effective March 31, 2026; John Mastrototaro transitioned to COO on March 30, 2026.
  • Michael Leabman, former CTO, was terminated March 18, 2026, and is entitled to $375,000 cash severance.
  • CFO J. Cogan's annual base salary increased to $400,000, with $325,000 severance upon termination.
  • COO John Mastrototaro's annual base salary is $300,000, with $400,000 severance upon termination.
  • A new 2026 Director Compensation Policy includes a $65,000 annual board retainer and a $135,000 annual equity award.
MOVE
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Corvex, Inc.

Price Impact